March 2014

Breast cancer patients whose chemotherapy is initiated >60 days following surgery experience worse survival outcomes

The use of immunotherapy for pancreatic cancer has had limited exposure, but Aduro BioTech, Inc, has had phase II success with an approach in which two vaccines are administered. The vaccines, GVAX Pancreas and CRS-207, are administered to patients sequentially.

The Long-Term Follow-Up (LTFU) Clinical Program at Seattle Cancer Care Alliance (SCCA) has expanded its scope of services to assist in the hands-on management of patients who develop complex conditions more than 100 days after their peripheral blood hematopoietic stem cell transplant procedure

There is no question that the era of precision medicine has arrived, and we need to embrace it and resolve together the challenges that come with it, including at the regulatory level.

Founded in 1987, Gilead Sciences made a name for itself in 1996, when it launched Vistide, a treatment for cytomegalovirus retinitis in patients with AIDS.